Quantisnow Logo
Dashboard

Amendment: SEC Form SC 13G/A filed by OPKO Health Inc.

$OPK
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $OPK alert in real time by email
SC 13G/A 1 UnitedStates_13G__OPKOHealth.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* (Name of Issuer) OPKO Health Inc (Title of Class of Securities) Common Stock (CUSIP Number) 68375N103 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 68375N103 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 228,641 (7) Sole dispositive power 28,619,929 (8) Shared dispositive power 598,221 (9) Aggregate amount beneficially owned by each reporting person 29,218,150 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 4.18% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: OPKO Health Inc Item 1(b) Address of issuer's principal executive offices: 4400 Biscayne Blvd Suite 1180 Miami, FL 33137 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 68375N103 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 29,218,150 (b) Percent of class: 4.18% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 29,218,150 (b) Percent of class: 4.18% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 228,641 (iii) Sole power to dispose or to direct the disposition of: 28,619,929 (iv) Shared power to dispose or to direct the disposition of: 598,221 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Repo
Get the next $OPK alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OPK

DatePrice TargetRatingAnalyst
6/29/2023$2.00Mkt Perform → Outperform
Barrington Research
12/15/2022$3.00Buy
H.C. Wainwright
1/24/2022Outperform → Market Perform
Barrington Research
More analyst ratings

$OPK
 Press Releases

Fastest customizable press release news feed in the world

See more

  • OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

    MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) and Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement to advance into the clinic the first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment for patients with obesity, metabolic and fibrotic disorders. The program combines OPKO's proprietary long-acting oxyntomodulin analog (OPK-88006) and Entera's proprietary N-Tab™ technology. Favorable pharmacodynamic, pharmacokinetic and bioavailability data in vivo were reported in September 2024. The companies expect to file an In

    $ENTX
    $OPK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

  • Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

    Transaction to extend Labcorp's leadership in oncology and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI, March 11, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. Through this transaction, Labcorp will acquire Bi

    $LH
    $OPK
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

  • OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results

    MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the fourth quarter of 2024 and recent weeks include the following: Enrollment and dosing underway by Merck in the Phase 1 Epstein-Barr virus (EBV) vaccine trial. Dosing of patients has commenced for the Phase I study (NCT06655324) of an EBV vaccine candidate being developed in collaboration with Merck. The investigational vaccine, based on ModeX's ferritin nanoparticle vaccine platform, is being evaluated for safety and tolerability in up to 200 healthy adults. Commencement of this study triggere

    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

$OPK
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$OPK
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$OPK
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$OPK
 SEC Filings

See more

$OPK
 Leadership Updates

Live Leadership Updates

See more

  • OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development

    WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ:OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug development, including most recently as Vice President at Sanofi, where he provided executive leadership for advancing oncology assets. "Dr. Abbadessa's deep experience in leading early-stage oncology development makes him the ideal fit to steer development of our multispecific antibodies for cancer and other clinical indications," said Dr. Gary Nabel, co-founder, President and CEO of ModeX Thera

    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Jon Cohen and Michael Hansen Join Talkspace's Board of Directors

    NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Shareholders of Talkspace, Inc. (NASDAQ:TALK) today elected Jon Cohen, M.D., to the virtual behavioral healthcare company's board of directors and approved all other shareholder proposals during the company's first Annual Meeting of Stockholders. Dr. Cohen is prior Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President of OPKO Health (NASDAQ:OPK). Dr. Cohen brings 30 years of healthcare industry strategy and operating experience to Talkspace's board of directors. He succeeds Jeffrey Crowe as an independent Class I Director with a term expiring in 2025. Additionally, the Company's board appointed C

    $OPK
    $TALK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services

  • OPKO Health Appoints Katherine Stueland as President and CEO of GeneDx

    MIAMI, June 22, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., the global genomics subsidiary of OPKO's BioReference Laboratories. Ms. Stueland joins GeneDx from Invitae Corporation (NYSE:NVTA), where she served most recently as Chief Commercial Officer, establishing the corporate brand as Invitae evolved from a private company to a public entity with a market capitalization exceeding $6 billion.  "We're thrilled to have Katherine lead the team at GeneDx, which has served clinicians and patients for more than two decades with novel and differentiated technologies for di

    $OPK
    $NVTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

$OPK
 Financials

Live finance-specific insights

See more

  • OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results

    MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the fourth quarter of 2024 and recent weeks include the following: Enrollment and dosing underway by Merck in the Phase 1 Epstein-Barr virus (EBV) vaccine trial. Dosing of patients has commenced for the Phase I study (NCT06655324) of an EBV vaccine candidate being developed in collaboration with Merck. The investigational vaccine, based on ModeX's ferritin nanoparticle vaccine platform, is being evaluated for safety and tolerability in up to 200 healthy adults. Commencement of this study triggere

    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025

    MIAMI, Feb. 13, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets on Thursday, February 27, 2025. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on February 27th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operat

    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results

    MIAMI, Nov. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three and nine months ended September 30, 2024. Highlights from the third quarter of 2024 and recent weeks include the following: Completed sale of select assets of BioReference Health to Labcorp for $237.5 million. OPKO completed the sale of BioReference Health's laboratory testing businesses focused on clinical diagnostics and women's health, excluding operations in New York and New Jersey, for $237.5 million. BioReference Health will continue to offer oncology and urology diagnostic services nationwide, as well as maintain its full operations in New Yor

    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

$OPK
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more